In contrast to EGFR-mutated NSCLC models, EGFR signaling in GBM models failed to display reduction of both the activation of EGFRvIII and downstream kinases upon osimertinib treatment (Figure 2B). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.